Bernstein Flags “Bad Look” as Fiserv Appoints New CEO Just Weeks After Investor Day
Bernstein says Fiserv’s appointment of Takis Georgakopoulos as CEO has a “bad look,” coming just weeks after Investor Day while the stock is at 10-year lows.
NOTRELOAD AI
enGene Lays Off 50% of Staff and Stops Patient Enrollment to Save Cash
enGene is reducing its workforce by ~50% and has stopped patient enrollment in three additional LEGEND trial cohorts to preserve cash while focusing on its pivotal data and planned BLA filing.
Analysts Reiterate Buy Ratings on Intellia as lonvo-z Shows Deeper Benefits in HAELO Trial
Intellia’s one-time gene therapy cut HAE attacks ~90%, boosting hopes for a lasting treatment; FDA review underway, launch possible in 2027.
Oppenheimer Sees 440% Upside in Acrivon Therapeutics as Key ACR-368 Data Approaches
Cancer drug ACR-368 shows strong early results in endometrial trials biomarker-driven response.
Salesforce Acquires Fin for $3.6 Billion to Strengthen AI Customer Agents
The deal will expand its Agentforce platform with advanced AI-powered customer service agents.
Neumora Halts Navacaprant Development After Phase 3 Depression Trials Fail
Neumora stopped navacaprant after failed depression trials, cut 35% jobs, shares fell, but keeps advancing 3 other drugs.